Bivalirudin for cardiopulmonary bypass in a patient with heparin allergy.
Bivalirudin
Cardiopulmonary bypass
Heparin allergy
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
11 Sep 2023
11 Sep 2023
Historique:
received:
17
02
2022
accepted:
29
08
2023
medline:
13
9
2023
pubmed:
12
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Hypersensitivity reactions to heparin are uncommon conditions but pose a serious clinical problem for patients requiring cardiopulmonary bypass. Bivalirudin is a reversible direct thrombin inhibitor that can be used instead of heparin. A 49-year-old male patient was admitted to our hospital for coronary artery bypass graft operation with mitral insufficiency and tricuspid valve insufficiency. Heparin allergy was confirmed by skin biopsy and skin tests. Due to this allergy, we used bivalirudin (Bivacard VEM drug, Turkey) during the surgery. A loading dose of 1.0 mg/kg (100 mg) bivalirudin was administered through the central line and a continuous infusion of 2.5 mg/kg/h of the anticoagulant was initiated following the approved protocol. Serial ACTs were obtained at 15-minute intervals during the procedure and the measurements were 330s, 320s, 350s, 360s, and 340s consecutively. Additional boluses of 0.5 mg/kg (50 mg) were administered for each measurement. Left anterior descending, obtuse marginal arteries and the right coronary artery were grafted with the left internal mammary and saphenous veins. Also, mitral valve replacement with St Jude mechanical heart valve and tricuspid ring annuloplasty was performed with Medtronic Duran ring. After the surgery, the patient had an uneventful period in the postoperative intensive care unit with a total of 600ml and 300ml chest tube drainage for two days and was discharged on the 7th day. Alternative anticoagulation strategies are needed for cardiopulmonary bypass in patients unable to use heparin. Bivalirudin may be recommended as a viable alternative anticoagulant in patients with heparin allergy during cardiopulmonary bypass. However, each patient should be evaluated individually and it should not be forgotten that more than recommended doses may be needed.
Sections du résumé
BACKGROUND
BACKGROUND
Hypersensitivity reactions to heparin are uncommon conditions but pose a serious clinical problem for patients requiring cardiopulmonary bypass. Bivalirudin is a reversible direct thrombin inhibitor that can be used instead of heparin.
CASE REPORT
METHODS
A 49-year-old male patient was admitted to our hospital for coronary artery bypass graft operation with mitral insufficiency and tricuspid valve insufficiency. Heparin allergy was confirmed by skin biopsy and skin tests. Due to this allergy, we used bivalirudin (Bivacard VEM drug, Turkey) during the surgery. A loading dose of 1.0 mg/kg (100 mg) bivalirudin was administered through the central line and a continuous infusion of 2.5 mg/kg/h of the anticoagulant was initiated following the approved protocol. Serial ACTs were obtained at 15-minute intervals during the procedure and the measurements were 330s, 320s, 350s, 360s, and 340s consecutively. Additional boluses of 0.5 mg/kg (50 mg) were administered for each measurement. Left anterior descending, obtuse marginal arteries and the right coronary artery were grafted with the left internal mammary and saphenous veins. Also, mitral valve replacement with St Jude mechanical heart valve and tricuspid ring annuloplasty was performed with Medtronic Duran ring. After the surgery, the patient had an uneventful period in the postoperative intensive care unit with a total of 600ml and 300ml chest tube drainage for two days and was discharged on the 7th day.
CONCLUSION
CONCLUSIONS
Alternative anticoagulation strategies are needed for cardiopulmonary bypass in patients unable to use heparin. Bivalirudin may be recommended as a viable alternative anticoagulant in patients with heparin allergy during cardiopulmonary bypass. However, each patient should be evaluated individually and it should not be forgotten that more than recommended doses may be needed.
Identifiants
pubmed: 37697290
doi: 10.1186/s13019-023-02359-2
pii: 10.1186/s13019-023-02359-2
pmc: PMC10496239
doi:
Substances chimiques
bivalirudin
TN9BEX005G
Heparin
9005-49-6
Anticoagulants
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
258Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Anesthesiology. 2018 Feb;128(2):390-400
pubmed: 29206646
J Thorac Cardiovasc Surg. 2005 Nov;130(5):1455-6
pubmed: 16256803
J Extra Corpor Technol. 2014 Jun;46(2):170-2
pubmed: 25208436
Eur J Cardiothorac Surg. 2008 Nov;34(5):1113-4
pubmed: 18760617
J Cardiothorac Surg. 2011 Apr 08;6:44
pubmed: 21477293
J Thorac Cardiovasc Surg. 2006 Mar;131(3):533-9
pubmed: 16515902
Eur J Haematol. 2007 Feb;78(2):161-6
pubmed: 17328717
J Card Surg. 2008 Nov-Dec;23(6):655-8
pubmed: 18793221
Chest. 2012 Feb;141(2 Suppl):e495S-e530S
pubmed: 22315270
Perfusion. 2007 Jan;22(1):67-9
pubmed: 17633138
Ann Thorac Surg. 2007 Feb;83(2):572-7
pubmed: 17257990
J Thorac Cardiovasc Surg. 2005 Jun;129(6):1391-4
pubmed: 15942583
Perfusion. 2001 Sep;16(5):411-6
pubmed: 11565896
J Cardiothorac Vasc Anesth. 2000 Jun;14(3):243-8
pubmed: 10890473
Ann Thorac Surg. 2018 Feb;105(2):650-662
pubmed: 29362176
J Extra Corpor Technol. 2005 Sep;37(3):296-302
pubmed: 16350384
Eur J Cardiothorac Surg. 2005 Jan;27(1):138-49
pubmed: 15621486
Am J Cardiol. 2004 Feb 1;93(3):356-9
pubmed: 14759391